Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glipizide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC8 known ✓ | Q09428 | 2/20 | 0.54 |
| ▸ | KCNJ11 known ✓ | Q14654 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 4/20 | 0.90 |
| ▸ | LMNA | P02545 | 3/20 | 0.90 |
| ▸ | BLM | P54132 | 3/20 | 0.90 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.90 |
| ▸ | MAPT | P10636 | 2/20 | 0.90 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.90 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.90 |
| ▸ | HTR1A | P08908 | 1/20 | 0.90 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.90 |
| ▸ | CNR1 | P21554 | 1/20 | 0.90 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.90 |
| ▸ | PPARG | P37231 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glipizide SCHEMBL1536893 | 0.95 | TSHR (1.00) | TSHRLMNABLMCYP2C9CYP3A4 | |
| Glipizide SCHEMBL17094 | 0.95 | TSHR (1.00) | TSHRLMNABLMCYP2C9CYP3A4 | |
| Glipizide SCHEMBL29366401 | 0.95 | TSHR (1.00) | TSHRLMNABLMCYP2C9CYP3A4 | |
| Glipizide SCHEMBL28867262 | 0.94 | TSHR (0.98) | TSHRLMNABLMCYP2C9CYP3A4 | |
| Glipizide SCHEMBL27728874 | 0.94 | TSHR (0.98) | TSHRLMNABLMCYP2C9CYP3A4 | |
| Glipizide SCHEMBL27573879 | 0.94 | TSHR (0.98) | TSHRLMNABLMCYP2C9CYP3A4 | |
| Glipizide SCHEMBL2057153 | 0.94 | TSHR (0.98) | TSHRLMNABLMCYP2C9CYP3A4 | |
| Glipizide SCHEMBL7716609 | 0.90 | LMNA (0.90) | TSHRLMNABLMCYP2C9CYP3A4 | |
| Glipizide SCHEMBL13427376 | 0.90 | LMNA (0.90) | TSHRLMNABLMCYP2C9CYP3A4 | |
| Glipizide SCHEMBL2323879 | 0.88 | LMNA (0.77) | TSHRLMNABLMCYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3362071-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | Grünenthal GmbH (DE) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017049294-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2011097269-A9 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| EP-2531200-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | Thar Pharmaceuticals, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011097269-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |